ASH 2022: Triplet Therapy Effective for High-Risk Chronic Lymphocytic Leukemia
Undetectable minimal residual disease achieved in 83 percent of high-risk patients at 35 months of follow-up
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.